Novel epilepsy treatments in clinical development

Area of Science:

• Neurology
• Pharmacology
• Biotechnology

Background:

• Epilepsy affects millions, with one-third of patients resistant to current antiseizure medications (ASMs).
• Existing ASMs offer symptomatic relief but do not address the underlying disease and can have significant side effects.
• There is a critical need for novel epilepsy treatments with improved efficacy and disease-modifying potential.

Purpose of the Study:

• To review emerging epilepsy treatments currently in clinical development.
• To categorize these investigational therapies into novel small molecules, gene-targeted approaches, and therapeutic devices.
• To highlight trends in epilepsy drug development, including a focus on rare syndromes and etiological targets.

Main Methods:

• Narrative review of epilepsy treatments in clinical development.
• Categorization of treatments into small molecules, gene therapies (antisense oligonucleotides, vector gene therapies, cell-based therapies), and therapeutic devices.
• Analysis of trends and potential impact of these novel therapies.

Main Results:

• Investigational treatments include novel small-molecule chemical entities, gene-targeted therapies, and therapeutic devices.
• Many new treatments focus on rare epilepsy syndromes and aim to modify the disease's underlying etiology.
• Preliminary efficacy data suggest promise for treatments targeting neurodevelopment and comorbidities.

Conclusions:

• Emerging epilepsy treatments show potential to overcome limitations of current pharmacotherapy.
• Gene-targeted therapies and etiological treatments offer hope for modifying disease trajectory and improving outcomes.
• These advancements provide hope for patients with drug-resistant epilepsy and unmet therapeutic needs.